Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Huntington's Disease 123

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03434548
Recruitment Status : Not yet recruiting
First Posted : February 15, 2018
Last Update Posted : September 18, 2018
Sponsor:
Information provided by (Responsible Party):
King's College London

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary goal of the program is to derive biomarkers that could be further developed to measure the efficacy of novel pharmacological treatments for HD.

Condition or disease
Huntington Disease

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 150 participants
Observational Model: Case-Control
Time Perspective: Other
Official Title: Huntington's Disease 123
Estimated Study Start Date : April 1, 2019
Estimated Primary Completion Date : March 31, 2024
Estimated Study Completion Date : March 31, 2024

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Cohort 1
Healthy Controls
Cohort 2
Huntington's Disease Gene Expansion Carriers (HDGECs: premanifest near-onset, peri-manifest, and manifest), and Healthy Controls


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in binding profile of four discrete molecular PET markers [ Time Frame: From study enrolment up to 24 months ]
    Determine whether selected PET markers could be used as markers of HD disease progression and treatment response in therapeutic trials.


Biospecimen Retention:   Samples With DNA
Analysis will be performed to confirm the size of the CAG expansion mutation within the HD gene for all HDGEC participants, for research purposes only.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Healthy controls (HCs) and Huntington's Disease Gene Expansion Carriers (HDGECs).
Criteria

Inclusion Criteria:

  • Must be capable of giving informed consent
  • Must be willing to comply with adequate contraceptive measures
  • Must be considered by the Investigator to be in good heath (excluding disease under study)

Exclusion Criteria:

  • Individuals who do not meet inclusion criteria
  • Known intracranial comorbidities (i.e. stroke, haemorrhage, space-occupying lesions etc.)
  • The presence or history of other neurological or primary psychiatric disorders secondary to HD
  • Pregnancy
  • Breastfeeding
  • Contraindication to MRI (e.g. presence of metal devices, metal deposited in the body)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03434548


Contacts
Layout table for location contacts
Contact: Chloe Farrell, PhD 00442078485452 chloe.farrell@kcl.ac.uk

Sponsors and Collaborators
King's College London
Investigators
Layout table for investigator information
Principal Investigator: Chloe Farrell, PhD King's College London
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: King's College London
ClinicalTrials.gov Identifier: NCT03434548    
Other Study ID Numbers: HD123
First Posted: February 15, 2018    Key Record Dates
Last Update Posted: September 18, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Huntington Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Dementia
Chorea
Dyskinesias
 Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Cognition Disorders
Neurocognitive Disorders
Mental Disorders